An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
Open Access
- 1 July 2021
- journal article
- review article
- Published by Informa UK Limited in Drug Design, Development and Therapy
- Vol. ume 15, 2987-2998
- https://doi.org/10.2147/dddt.s317382
Abstract
Biologic drugs have revolutionized the treatment of psoriasis and other rheumatological diseases. In recent years, many biosimilar agents that are highly similar in structure and function to their originator products have been developed, including the tumor necrosis factor-alpha antagonist adalimumab. The considerably lower cost of these products has greatly cut the economic burden of the patients and increased the accessibility of biologic therapies worldwide. The US Food and Drug Administration and/or the European Medicines Agency have approved eight biosimilars of adalimumab (ABP 501/BI 695501/SB5/GP2017/FKB327/MSB11022/PF-06410293/CT-P17) for the treatment of psoriasis, and others are under review. Given that these agents showed pharmacokinetic, efficacy, safety, and immunogenicity profiles comparable to those of the originator, adalimumab biosimilars were licensed for all indications approved for reference adalimumab based on extrapolation; however, some of the equivalence studies were only conducted in one or two disease populations. This review discusses the bioequivalence of adalimumab biosimilars as demonstrated by various clinical trials, the extrapolation of indications, guidance and policies of the EU and US on interchangeability (nonmedical switching/automatic substitution) between biosimilars and originators, and the real-life practices of switching from reference adalimumab to the respective biosimilars. Further data from real-world studies and post-marketing analyses are needed better to address the efficacy and safety of the transition strategy.Keywords
This publication has 49 references indexed in Scilit:
- Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsExpert Opinion on Investigational Drugs, 2016
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty PhysiciansAdvances in Therapy, 2016
- A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumabAnnals Of The Rheumatic Diseases, 2016
- Humira: the impending patent battles over adalimumab biosimilarsPharmaceutical Patent Analyst, 2016
- Budget Impact Analysis of An Etanercept Biosimilar for The Treatment of Rheumatoid Arthritis In EuropeValue in Health, 2015
- Comparison between different D‐Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS studyInternational Journal of Laboratory Hematology, 2015
- A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritisInternational Journal of Rheumatic Diseases, 2015
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trialsArthritis & Rheumatism, 2006